Dear Friend,
On Monday, we shared the exciting news that the FDA has approved TRIKAFTA™ for people with cystic fibrosis age 12 and older who have at least one copy of the F508del mutation. With the introduction of this triple-combination modulator, more than 90 percent of people with CF could eventually have a highly effective therapy for the underlying cause of their disease.
The CF community is invited to a Community Q&A Webinar on Friday, October 25 from 4:00 - 4:30 pm ET to learn more about this important milestone.
| |
We will be joined by Michael Boyle, MD, SVP of Therapeutics Development, Mary Dwight, SVP of Policy and Advocacy, and Bruce Marshall, MD, SVP of Clinical Affairs, who will discuss the research behind the triple combination therapy, questions around access, and how this breakthrough is expected to impact the health of those approved for the drug.
We hope you are able to join us! If you are unable to watch live, all those who register will receive a link to the webinar recording and an FAQ based on the community’s questions in the days after the event.
| |
|
|
|
|
